Sibylle Haemmerle
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Urticaria and Related Conditions, Autoimmune Bullous Skin Diseases, Psoriasis: Treatment and Pathogenesis, Eosinophilic Disorders and Syndromes, Spondyloarthritis Studies and Treatments
Most-Cited Works
- → Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study(2012)356 cited
- → Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study(2020)155 cited
- → Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria(2022)144 cited
- → Remibrutinib in Chronic Spontaneous Urticaria(2025)65 cited
- → Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks(2023)61 cited
- → Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5(2020)46 cited
- → Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT(2021)43 cited
- → Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study(2017)41 cited
- → Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)(2018)32 cited
- → Secukinumab improves the signs and symptoms of moderate‐to‐severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double‐blind, placebo‐controlled, phase 2 dose‐ranging study(2013)22 cited